NewAmsterdam Pharma (NAMS) grants RSUs and stock options to director

Rhea-AI Filing Summary

NewAmsterdam Pharma Co. N.V. director Adele M. Gulfo reported equity awards in the form of ordinary shares and options. On January 7, 2026, she received 3,400 restricted stock units (RSUs), each representing one ordinary share, bringing her directly held ordinary shares to 14,260. The RSUs were granted for no cash consideration and will fully vest on the one-year anniversary of the vesting start date, subject to her continued service.

On the same date, she was also granted an option to purchase 15,300 ordinary shares at an exercise price of $35.45 per share, with 15,300 options owned following the grant. All shares underlying the option are scheduled to vest on January 2, 2027, also conditioned on her continued service.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Gulfo Adele M.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Option (right to buy)	15,300	$0.00	--
Grant/Award	Ordinary Shares	3,400	$0.00	--

Holdings After Transaction: Option (right to buy) — 15,300 shares (Direct); Ordinary Shares — 14,260 shares (Direct)

Footnotes (1)

1. Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. All of the RSUs will vest on the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date. Each RSU was granted on January 7, 2026 for no consideration. All of the ordinary shares underlying the option will vest on January 2, 2027, the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gulfo Adele M.

(Last) (First) (Middle)

C/O NEWAMSTERDAM PHARMA COMPANY N.V.

GOOIMEER 2-35

(Street)

NAARDEN P7 1411 DC

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NewAmsterdam Pharma Co N.V. [ NAMS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/07/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	01/07/2026		A		3,400(1)	A	(2)	14,260	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (right to buy)	$35.45	01/07/2026		A		15,300		(3)	01/07/2036	Ordinary Shares	15,300	$0.00	15,300	D

Explanation of Responses:

1. Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. All of the RSUs will vest on the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date.

2. Each RSU was granted on January 7, 2026 for no consideration.

3. All of the ordinary shares underlying the option will vest on January 2, 2027, the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date.

	/s/ Louise Kooij by Power of Attorney from Adele Gulfo	01/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who is the insider in this NewAmsterdam Pharma (NAMS) Form 4 filing?

The reporting person is Adele M. Gulfo, who serves as a director of NewAmsterdam Pharma Co. N.V.

What equity awards did Adele Gulfo receive from NewAmsterdam Pharma (NAMS)?

She received 3,400 RSUs representing ordinary shares and an option to buy 15,300 ordinary shares at an exercise price of $35.45 per share.

When do Adele Gulfo’s NewAmsterdam Pharma RSUs vest?

All of the 3,400 RSUs will vest on the one-year anniversary of the vesting start date, subject to her continued service.

When do the stock options granted to Adele Gulfo by NewAmsterdam Pharma vest?

All ordinary shares underlying the 15,300-share option will vest on January 2, 2027, the one-year anniversary of the vesting start date, if she continues in service through that date.

How many NewAmsterdam Pharma ordinary shares does Adele Gulfo own after these transactions?

After the reported transactions, she beneficially owns 14,260 ordinary shares directly, along with 15,300 stock options.

Did Adele Gulfo pay cash for the RSUs granted by NewAmsterdam Pharma?

No. Each RSU was granted on January 7, 2026 for no consideration, meaning there was no cash payment for the grant.